Figure 4
UCP1-independent effects of C12TPP in mice. (a) Food intake for 16 days of pretreatment and treatment period in the wild-type and UCP1-KO mice on HFD at thermoneutrality. The data for wild-type mice were obtained from Figure 1f. (b) Body fat mass on day 0 (the start of C12TPP treatment) and on the 16th (last) day of treatment in wild-type and UCP1-KO mice. The data for wild-type mice were obtained from Figure 1c. In a and b, the values are means±s.e.m. (n=8 in each group). The data were statistically analyzed with a two-way mixed analysis of variance (ANOVA) with treatment as within-subjects factor and genotype as between-subjects factor: in a, (genotype: P<0.01; treatment: P<0.001; interaction ns); in b, (genotype: P<0.01; day: P<0.001; interaction ns). °Significant differences between days (pretreatment and treatment, or day 0 and day 16); #Significant differences between genotypes. (c) Western blotting of mitochondrial proteins in the total interscapular BAT (iBAT) protein extract from UCP1-KO mice treated with C12TPP for 16 days on a HFD at thermoneutrality. (d) Mitochondrial protein content per mg tissue extract taken from quantification of western blotting as in c. (e) iBAT total protein content. (f) Mitochondrial protein content per total iBAT depot. In d–f, the mean and individual data points of four independent tissue extracts of each group are presented. For graphic presentation on d–f, the mean protein level of control iBAT was defined as 100% and the levels in iBAT from C12TPP-treated mice expressed relatively to this value. For statistics on d–f, the raw data were analyzed with Wilcoxon–Mann–Whitney test. Asterisks indicate significant differences between the control and C12TPP-treated groups.
